Ocular damage associated with proton pump inhibitors.
作者信息
Schönhöfer P S, Werner B, Tröger U
机构信息
Institute of Clinical Pharmacology, Bremen, Germany.
出版信息
BMJ. 1997 Jun 21;314(7097):1805. doi: 10.1136/bmj.314.7097.1805.
Abstract
摘要
相似文献
1
Ocular damage associated with proton pump inhibitors.与质子泵抑制剂相关的眼部损害。
BMJ. 1997 Jun 21;314(7097):1805. doi: 10.1136/bmj.314.7097.1805.
2
Omeprazole (correction of omepraxole) and ocular damage. Facts of cases are unclear.奥美拉唑（纠正为omeprazole）与眼部损伤。病例情况不明。
BMJ. 1998 Jan 3;316(7124):67; author reply 68.
3
Omeprazole (correction of omepraxole) and ocular damage. Lack of causality holds true.奥美拉唑（纠正为omeprazole）与眼部损伤。不存在因果关系，此结论成立。
BMJ. 1998 Jan 3;316(7124):67-8.
4
Omeprazole (correction of omepraxole) and ocular damage. Concerns on safety of drug are unwarranted.奥美拉唑（纠正：奥美拉唑）与眼部损伤。对该药物安全性的担忧是毫无根据的。
BMJ. 1998 Jan 3;316(7124):67; author reply 68.
5
[Two cases of ocular damage associated with proton pump inhibitors].
Nihon Shokakibyo Gakkai Zasshi. 2000 May;97(5):575-9.
6
[Photodistributed cutaneous drug reaction induced by proton pump inhibitors].[质子泵抑制剂引起的光分布性皮肤药物反应]
Therapie. 2005 Jan-Feb;60(1):85-7. doi: 10.2515/therapie:2005012.
7
Proton-pump inhibitors and hypomagnesemic hypoparathyroidism.质子泵抑制剂与低镁血症性甲状旁腺功能减退症。
N Engl J Med. 2006 Oct 26;355(17):1834-6. doi: 10.1056/NEJMc066308.
8
Proton pump inhibitors.
Br Dent J. 2010 Feb 27;208(4):147. doi: 10.1038/sj.bdj.2010.162.
9
Omeprazole in oesophageal reflux disease.
Lancet. 2000 Nov 18;356(9243):1770-1. doi: 10.1016/S0140-6736(05)71964-4.
10
Omeprazole and excessive sweating, if unrecognised, may lead to unnecessary investigations.
Postgrad Med J. 1999 Nov;75(889):701-2. doi: 10.1136/pgmj.75.889.701.
引用本文的文献
1
Should evidence of an autolysosomal de-acidification defect in Alzheimer and Parkinson diseases call for caution in prescribing chronic PPI and DMARD?在阿尔茨海默病和帕金森病中，如果有证据表明自溶体去酸化缺陷，是否应该谨慎开处长期使用的质子泵抑制剂和 DMARD？
Autophagy. 2023 Oct;19(10):2800-2806. doi: 10.1080/15548627.2023.2214960. Epub 2023 Jul 23.
2
Statins and renal disease progression, ophthalmic manifestations, and neurological manifestations in veterans with diabetes: A retrospective cohort study.他汀类药物与糖尿病退伍军人的肾脏疾病进展、眼部表现和神经系统表现：一项回顾性队列研究。
PLoS One. 2022 Jul 21;17(7):e0269982. doi: 10.1371/journal.pone.0269982. eCollection 2022.
3
Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory.质子泵抑制剂的使用与广泛的神经系统不良事件相关，包括听力、视力和记忆力受损。
Sci Rep. 2019 Nov 21;9(1):17280. doi: 10.1038/s41598-019-53622-3.
4
Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database.与质子泵抑制剂相关的肌肉不良反应：使用意大利国家药物警戒数据库网络进行的不成比例分析
Drug Saf. 2017 Oct;40(10):895-909. doi: 10.1007/s40264-017-0564-8.
5
Proton Pump Inhibitors and Risk of Rhabdomyolysis.质子泵抑制剂与横纹肌溶解症风险
Drug Saf. 2017 Jan;40(1):61-64. doi: 10.1007/s40264-016-0473-2.
6
Omeprazole-associated rhabdomyolysis.奥美拉唑相关性横纹肌溶解症。
Crit Care. 2014 Jul 24;18(4):462. doi: 10.1186/s13054-014-0462-8.
7
Do proton pump inhibitors protect against cancer progression in GERD?质子泵抑制剂是否能预防 GERD 患者癌症进展？
Surg Today. 2013 Aug;43(8):831-7. doi: 10.1007/s00595-012-0395-2. Epub 2012 Oct 31.
8
Safety of the long-term use of proton pump inhibitors.质子泵抑制剂长期使用的安全性。
World J Gastroenterol. 2010 May 21;16(19):2323-30. doi: 10.3748/wjg.v16.i19.2323.
9
Esomeprazole-induced rhabdomyolysis in a patient with heart failure.一名心力衰竭患者出现埃索美拉唑诱发的横纹肌溶解症。
Intensive Care Med. 2010 Jul;36(7):1278-9. doi: 10.1007/s00134-010-1854-0. Epub 2010 Mar 13.
10
Safety profile of esomeprazole: results of a prescription-event monitoring study of 11 595 patients in England.埃索美拉唑的安全性概况：英国11595例患者的处方事件监测研究结果
Drug Saf. 2008;31(4):313-23. doi: 10.2165/00002018-200831040-00005.
Zotero 插件